Researchers have identified a new kind of small-cell lung cancer (SCLC) that may pave the way for developing personalised medicine approaches to target this previously unnoticed form of the disease.

According to the researchers, chemotherapy, radiotherapy, and surgery enable only 6 per cent of patients to survive five years from the time of their diagnosis and about 10 to 15 per cent of all lung cancers are SCLC.